La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Evaxion Biotech Bilan de santé

Santé financière contrôle des critères 3/6

Evaxion Biotech has a total shareholder equity of $1.3M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $15.2M and $21.1M respectively.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$11.73m
Fonds propres	US$1.25m
Total du passif	US$21.06m
Total des actifs	US$15.23m

Mises à jour récentes de la santé financière

Is Evaxion Biotech (NASDAQ:EVAX) In A Good Position To Invest In Growth?

Oct 27

We're Hopeful That Evaxion Biotech (NASDAQ:EVAX) Will Use Its Cash Wisely

Jun 29

Recent updates

Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration

Mar 31

Evaxion Biotech names Per Norlén as CEO

Oct 05

Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer

Sep 21

Evaxion Biotech posts preclinical proof of concept data for AI-powered vaccine platform

Jun 03

Analyse de la situation financière

Passif à court terme: EVAX's short term assets ($11.7M) exceed its short term liabilities ($7.1M).

Passif à long terme: EVAX's short term assets ($11.7M) do not cover its long term liabilities ($14.0M).

Historique et analyse du ratio d'endettement

Niveau d'endettement: EVAX is debt free.

Réduire la dette: EVAX has no debt compared to 5 years ago when its debt to equity ratio was 97.8%.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: EVAX has less than a year of cash runway based on its current free cash flow.

Prévisions de trésorerie: EVAX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 23.3% each year

Evaxion Biotech Bilan de santé

Santé financière contrôle des critères 3/6

Informations clés

Mises à jour récentes de la santé financière

Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Is Evaxion Biotech (NASDAQ:EVAX) In A Good Position To Invest In Growth?

We're Hopeful That Evaxion Biotech (NASDAQ:EVAX) Will Use Its Cash Wisely

Recent updates

Evaxion Biotech A/S to Report Q2, 2024 Results on Aug 14, 2024

Evaxion Biotech A/S Announces Publication of Data from Its Phase 1 Dose Escalation Study of Its Lead Personalized Cancer Vaccine, EVX-01

Consensus revenue estimates decrease by 97%, EPS upgraded

Consensus revenue estimates decrease by 24%, EPS upgraded

New major risk - Financial position

Evaxion Biotech A/S to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

Evaxion Announces Phase 2 Clinical Trial Update

Evaxion and Undisclosed Collaborator Announce Encouraging Results for Evx-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Consensus revenue estimates increase by 33%, EPS downgraded

Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration

Evaxion Biotech A/S, Annual General Meeting, Apr 16, 2024

Forecast to breakeven in 2025

Evaxion Biotech A/S has completed a Follow-on Equity Offering in the amount of $15 million.

New major risk - Negative shareholders equity

Evaxion Biotech A/S to Develop Tailored Novel Cancer Vaccines Based Upon A New Untapped Source of Ai-Discovered Targets

Evaxion Biotech A/S announced that it expects to receive $5.291433 million in funding from Merck Global Health Innovation Fund, LLC

Evaxion Biotech A/S announced that it expects to receive $5.291433 million in funding from Merck Global Health Innovation Fund, LLC

Evaxion Biotech A/S Announces Encouraging Initial Phase 2 Clinical Data on its Personalised Cancer Vaccine EVX-01

New and Exciting Clinical Data on Evaxion's Ai-Immunology™?-Based Personalized Cancer Vaccines to Be Presented

Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

Evaxion Biotech A/S Expands Preclinical Bacterial Vaccine Pipeline in Collaboration with Leading Pharmaceutical Company

Evaxion Biotech A/S Announces New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development

Evaxion Biotech A/S Appoints Christian Kanstrup as Chief Executive Officer

Evaxion Biotech A/S announced that it expects to receive $20 million in funding from Negma Group Investment Ltd

Evaxion Biotech A/S Plans to Announce the Interim Results of the Clinical Phase 2 Study with EVX-01 in Patients with Metastatic Melanoma in Fourth Quarter 2023

Evaxion Unveils Genetic Adjuvant Technology to Boost Vaccines

Forecast to breakeven in 2024

Evaxion Unveils Proprietary Genetic Aduvant Technology to Boost the Effect of Dna and Mrna Vaccines

Evaxion Biotech A/S, Annual General Meeting, May 24, 2023

Evaxion Biotech A/S and Pantherna Therapeutics GmbH Announce Promising Preclinical mRNA Vaccine Data

Evaxion Receives FDA Fast-Track Designation for Personalized Cancer Immunotherapy

Evaxion Receives Phase IIb Go-Ahead from FDA

Evaxion Biotech A/S Receives Approval from FDA to Proceed with the Clinical Phase 2B Study for Evx-01

Evaxion Biotech Reaches an Important Milestone When Enrolled Its First Patient in Perth, Australia in the Company's Global Phase 2B Clinical Trial of EVX-01

Evaxion Biotech A/S Announces Promising Results from Phase 1/2a Clinical Trial of Personalized DNA Cancer Immunotherapy EVX-02

Price target decreased to US$14.67

Evaxion Biotech A/S Welcomes Per Norlén as New CEO

Evaxion Biotech names Per Norlén as CEO

Evaxion Biotech A/S Enrols First Patient in Phase Iib Melanoma Study

Evaxion Biotech A/S Enrolls First Patient in the Global Phase 2B Clinical Trial of EVX-01

Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer

Forecast to breakeven in 2024

Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10

Evaxion Biotech A/S Announces Executive Management Changes

Evaxion Biotech announces new CEO as Lars Wegner resigns

Evaxion Biotech A/S Announces Gonorrhea as Second Bacterial Product Target

Evaxion Biotech Expands its EVX-03 DNA Vaccine Program into Non-Small Cell Lung Cancer

Evaxion Biotech A/S announced that it expects to receive $40 million in funding from Lincoln Park Capital, LLC

Evaxion Biotech A/S Approves Election of Niels Iversen Møller as New Member of the Board of Directors

Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2A Clinical Trial for EVX-02

Evaxion Biotech A/S, Annual General Meeting, May 03, 2022

Evaxion Biotech A/S Announces Executive Changes

Evaxion Biotech A/S Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02

Evaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading into Phase 2b in Collaboration with Merck

Evaxion Biotech Receives Regulatory Clearance to Initiate Phase 2 Trial of EVX-01 in Combination with KEYTRUDA® for Treatment of Melanoma

Is Evaxion Biotech (NASDAQ:EVAX) In A Good Position To Invest In Growth?

We're Hopeful That Evaxion Biotech (NASDAQ:EVAX) Will Use Its Cash Wisely

Evaxion Biotech Reports Preclinical Proof of Concept Data for Evaxion’s AI-powered Vaccine Platform RAVEN for the Design of a Next Generation SARS-CoV-2 Vaccine

Independent Director Helen Boudreau has left the company

Evaxion Biotech posts preclinical proof of concept data for AI-powered vaccine platform

Evaxion Biotech A/S has completed an IPO in the amount of $30 million.

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines